2026 ACC/AHA Guidelines Endorse Amarin’s Icosapent Ethyl for Cardiovascular Risk Management — Amarin Corporation plc

Event summary

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Update recommends icosapent ethyl (IPE) for managing cardiovascular risk in high-risk patients with elevated triglycerides.
The guideline highlights that IPE is the only triglyceride-lowering therapy proven to reduce atherosclerotic cardiovascular disease (ASCVD) events when added to statin therapy.
Amarin’s VASCEPA/VAZKEPA (icosapent ethyl) has been prescribed over 30 million times globally and is FDA-approved to reduce cardiovascular events in high-risk patients.
The guideline distinguishes IPE from other triglyceride-lowering agents like fenofibrates, which do not reduce cardiovascular risk when added to statin therapy.

The big picture

The 2026 ACC/AHA guideline update represents a significant validation of Amarin’s icosapent ethyl as a critical therapy for managing residual cardiovascular risk in high-risk patients. This endorsement aligns with broader industry trends toward prevention-first management of cardiovascular disease, emphasizing the need for complementary therapies beyond statin monotherapy. The guideline’s distinction of IPE from other triglyceride-lowering agents underscores its unique position in the market, potentially driving further adoption and reimbursement discussions globally.

What we're watching

Market Adoption: The pace at which the 2026 guideline update will drive increased adoption of icosapent ethyl in clinical practice, particularly among high-risk patients with elevated triglycerides.
Competitive Positioning: Whether Amarin can sustain its competitive edge as the only provider of a triglyceride-lowering therapy proven to reduce ASCVD events, especially as other cardiovascular societies align with the guideline recommendations.
Regulatory Alignment: How global regulatory bodies will respond to the updated guideline, particularly in regions where Amarin seeks to expand the approval and reimbursement of icosapent ethyl.